Oliceridine

Oliceridine is a DEA Schedule II controlled substance. Substances in the DEA Schedule II have a high potential for abuse which may lead to severe psychological or physical dependence. It is a Opiates substance. Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors. Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid receptor subtype is predominantly targeted by and is responsible for the effects of opioid agonists. However, due to the ability of some opioid agonists to bind to other targets, as well as activation of additional downstream pathways from opioid receptors including those involving β-arrestin, the beneficial analgesic effects of opioids are coupled with severe adverse effects including constipation and respiratory depression. Oliceridine (formerly known as TRV130) is a “biased agonist” at the μ-opioid receptor by preferentially activating the G-protein pathway with minimal receptor phosphorylation and recruitment of β-arrestin. By acting as a biased agonist, oliceridine provides comparable analgesia compared with traditional opioids including [morphine] at a comparable or decreased risk of opioid-related adverse effects including constipation and respiratory depression. Oliceridine was first reported in 2013, but was initially not approved by the FDA due to concerns raised by the Anesthetic and Analgesic Drug Products Advisory Committee. Oliceridine gained FDA approval on August 7, 2020, and is currently marketed by Trevena Inc as OLINVYK™. Oliceridine is an intravenously administered, synthetic opioid that is used to treat moderate-to-severe pain not responsive to nonsteroidal antiinflammatory agents. Oliceridine is associated with a low rate of serum aminotransferase elevations during therapy but has not been linked to instances of clinically apparent liver injury. It is grouped under the following drug class(es): QTc-prolonging agents. Its therapeutic use is listed as analgesics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Olinvyk, oliceridina, oliceridinum, Olinvo and Olinvik. It is listed as a controlled drug substance (Schedule II). Its PubChem CID is 66553195.

CAS No 1401028-24-7
Molecular Formula C22H30N2O2S
Molecular Weight 386.6 g/mol
Synonyms N-[(3-methoxythiophen-2-yl)methyl]-2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethanamine

Frequently Asked Questions